Drug Trial Radar · NCT06915246
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
49
Planned (sponsor's estimate)
Start
Mar 12, 2025
Primary completion
Mar 31, 2027
Study completion Apr 30, 2027
Sponsor
- Lead sponsor
- VIVUS LLCIndustry
- Sponsor type
- Industry
- First posted
- Apr 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase 2 multicenter study of VI-0609 vs BiCNU in the BEAM high-intensity conditioning regimen for AHCT in subjects with lymphomas.
Conditions
- Lymphoma
- Non-Hodgkin Lymphoma
- Hodgkin Lymphoma
Interventions
VI-0609Drug
Carmustine with Propylene Glycol
BiCNUDrug
Carmustine with Ethanol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation of infusion-related toxicitiesTime frame: Within 24 hours post infusion
- Evaluation of unacceptable toxicitiesTime frame: From start of BEAM through Day 30 post-AHCT
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
City of Hope Phoenix
Goodyear, Arizona · Recruiting
City of Hope National Medical Center
Duarte, California · Recruiting
City of Hope Atlanta
Newnan, Georgia · Recruiting
City of Hope Chicago
Zion, Illinois · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.